Summary

The Federal Department of the Interior (EDI) is expanding the Narcotic Substances List Ordinance to include additional synthetic drugs. As of March 13, 2026, these new psychoactive substances are subject to the Narcotics Act – manufacture, trade, and use are punishable offenses. The measure is intended to protect the population from incalculable health risks and prevent Switzerland from becoming a marketplace for designer drugs.

Persons

  • Swissmedic (Swiss Agency for Therapeutic Products)

Topics

  • Designer drugs and synthetic drugs
  • Narcotics Act and regulation
  • Public health and prevention
  • International cooperation

Clarus Lead

The EDI is tightening control of designer drugs by expanding the Narcotic Substances List Ordinance. New psychoactive substances are now legally equated with narcotics. This measure addresses a central risk for decision-makers in health and security: synthetic drugs are continuously modified chemically to exploit legal loopholes – a classic cat-and-mouse game between authorities and illegal providers.

Detailed Summary

Designer drugs are artificially manufactured substances created in laboratories, marketed under terms such as "research chemicals" or "legal highs." Their primary risk lies in the lack of scientific evidence: there is little reliable knowledge about toxicity, addiction potential, and interactions. Consumers cannot assess the health consequences.

The EDI is responding to this dynamic through regular updates to the Narcotic Substances List. Swissmedic, together with national and international partner authorities, monitors new synthetic substance classes and initiates bans. Since December 2011, new substances have been continuously added; the list now comprises 320 individual substances and substance groups. The strategy pursues two objectives: to curb misuse early and prevent Switzerland from becoming a hub for designer drug trafficking.

Key Messages

  • The EDI is expanding the Narcotic Substances List to include additional psychoactive substances (effective as of March 13, 2026)
  • Designer drugs pose a significant health risk because their effects and side effects are not scientifically documented
  • Proactive regulation is intended to prevent synthetic drugs from circumventing laws through chemical modification

Critical Questions

  1. Evidence Quality: On what data basis does Swissmedic identify new psychoactive substances as subject to misuse? How quickly are substances added to the list after appearing on the market?

  2. Effectiveness of the Measure: Do previous bans (since 2011: 320 substances) show measurable reduction in designer drug use in Switzerland, or do bans merely lead to chemical modifications of new substances?

  3. International Coordination: What role do international partners play in early detection? Are European and global standards harmonized to prevent trade displacement?

  4. Implementation Risks: How is compliance with the ban monitored in online trade and cross-border activities? What resources are allocated for enforcement?

  5. Consumer Protection: Are persons with addiction disorders placed at greater risk by the ban if they resort to uncontrolled black market alternatives?

Source List

Primary Source: Federal Department of the Interior (EDI) – Press Release of March 13, 2026: "Protection Against Designer Drugs: Additional Psychoactive Substances Banned" https://www.news.admin.ch/de/newnsb/hXmiCIcEHgjJ4_gD3IllM

Legal Basis: Narcotic Substances List Ordinance (BetmVV-EDI, SR 812.121.11) https://www.fedlex.admin.ch/eli/cc/2011/363/de

Verification Status: ✓ March 13, 2026

This text was created with the assistance of an AI model. Editorial Responsibility: clarus.news | Fact-Check: March 13, 2026